We found that the knockdown or overexpression of KRT19 in MDA-MB231 or KU-CSLCs cells modulated cancer reprogramming and drug sensitivity, as compared to normal MDA-MB231 or KU-CSLCs. This evidence concerns the gene KRT19 and cancer.